Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -55.09% is 358% below its 4-year average of -12.02%, around the middle of its 4-year range (-173.68%–125.69%).
31.88% above its 12-month average of -80.88%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 11.93%.
EBITDA MARGIN
-55.09%
EBITDA MARGIN AVG TTM
-80.88%
EBITDA MARGIN AVG 3Y
-80.88%
EBITDA MARGIN AVG 5Y
-12.02%
EBITDA MARGIN AVG 10Y
-86.30%
EBITDA MARGIN AVG 15Y
-378.27%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+31.88%
CURRENT VS 3Y AVG
+31.88%
CURRENT VS 5Y AVG
-358.31%
CURRENT VS 10Y AVG
+36.16%
CURRENT VS 15Y AVG
+85.44%
CURRENT VS 20Y AVG
N/A
Omeros Corporation
Market Cap
$1.35B
EBITDA Margin
-55.09%
TTM Avg
-80.88%
3Y Avg
-80.88%
5Y Avg
-12.02%
Market Cap
$1.37B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
EBITDA Margin
-10195.54%
TTM Avg
-87388.52%
3Y Avg
-48181.08%
5Y Avg
-32386.50%
Market Cap
$1.42B
EBITDA Margin
6.32%
TTM Avg
6.34%
3Y Avg
5.49%
5Y Avg
5.03%
Market Cap
$1.44B
EBITDA Margin
21.45%
TTM Avg
-50.92%
3Y Avg
-538.26%
5Y Avg
-378.46%
Market Cap
$1.44B
EBITDA Margin
-74.29%
TTM Avg
-81.81%
3Y Avg
-115.58%
5Y Avg
-114.07%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Omeros Corporation (OMER) | $1.35B | -55.09% | -80.88% | -80.88% | -12.02% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.37B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.41B | -10195.54% | -87388.52% | -48181.08% | -32386.50% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 6.32% | 6.34% | 5.49% | 5.03% |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 21.45% | -50.92% | -538.26% | -378.46% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | -74.29% | -81.81% | -115.58% | -114.07% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-55.1%
Operating Margin
0.0%
Net Margin
324.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 11.93% |
| 2026-03-31 | -173.68% |
| 2021-12-31 | 125.69% |
| 2020-12-31 | -314.32% |
| 2020-09-30 | -95.83% |
| 2020-06-30 | -201.54% |
| 2020-03-31 | -98.89% |
| 2019-12-31 | -69.36% |
| 2019-09-30 | -35.72% |
| 2019-06-30 | -33.22% |
| 2019-03-31 | -86.61% |
| 2018-12-31 | -82.51% |
| 2018-09-30 | -764.26% |
| 2018-06-30 | -1837.52% |
| 2018-03-31 | -1729.60% |
| 2017-12-31 | -101.37% |
| 2017-09-30 | -22.93% |
| 2017-06-30 | -68.92% |
| 2017-03-31 | -102.88% |
| 2016-12-31 | -91.19% |
| 2016-09-30 | -105.85% |
| 2016-06-30 | -108.56% |
| 2016-03-31 | -261.48% |
| 2015-12-31 | -269.54% |
| 2015-09-30 | -590.58% |
| 2015-06-30 | -499.37% |
| 2015-03-31 | -4606.96% |
| 2014-12-31 | -11052.78% |
| 2014-09-30 | -7967.29% |
| 2014-06-30 | -38077.78% |
| 2014-03-31 | -15602.00% |
| 2013-12-31 | -8178.70% |
| 2013-09-30 | -6814.80% |
| 2013-06-30 | -9344.29% |
| 2013-03-31 | -908.95% |
| 2012-12-31 | -470.31% |
| 2012-09-30 | -915.24% |
| 2012-06-30 | -535.52% |
| 2012-03-31 | -533.36% |
| 2011-12-31 | -852.84% |
| 2011-09-30 | -613.48% |
| 2011-06-30 | -423.38% |
| 2011-03-31 | -507.02% |
| 2010-12-31 | -870.18% |
| 2010-09-30 | -2890.94% |
| 2010-06-30 | -1508.45% |
| 2010-03-31 | -1666.93% |
| 2009-12-31 | -1200.92% |
| 2009-09-30 | -1000.90% |
| 2009-06-30 | -1498.11% |
| 2009-03-31 | -2595.43% |
| 2008-12-31 | -3488.95% |
| 2008-09-30 | -1507.78% |
